A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.

Amy Jo ChienAlyson CockerillCraig FancourtEmmett SchmidtMark M MoasserHope S RugoMichelle E MeliskoAndrew H KoR Katie KelleyW Michael KornLaura J EssermanLaura van't VeerChristina YauDenise M WolfPamela N Munster

Published in: Breast cancer research and treatment (2016)

MK-2206 at a dose of 135 mg/week in combination with weekly paclitaxel and trastuzumab is safe and well tolerated, and is the recommended phase 2 dose for this combination. Preliminary data indicate significant clinical activity in patients with HER2+ tumors despite prior HER2-directed therapy.

Keyphrases

epidermal growth factor receptor
signaling pathway
cell proliferation
metastatic breast cancer
clinical trial
tyrosine kinase
bone marrow
data analysis
cell therapy
artificial intelligence